Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vaxcyte, Inc.
1-25 of 761 filings
Recent SEC filings with analysis
- 8-KVaxcyte closed a $575 million offering of 1.50% Convertible Senior Notes due 2032 on October 9, 2026, including full exercise of the underwriters' $75 million…
- 424B5Vaxcyte (Nasdaq: PCVX) is offering $500 million of 1.50% convertible senior notes due 2032, with a $75 million over-allotment option, at an initial conversion…
- 424B5Vaxcyte priced a $500M follow-on offering of 7,412,500 shares at $64.00 per share, plus pre-funded warrants on 400,000 shares, a roughly 4% discount to the…
- 424B5Vaxcyte filed a preliminary 424B5 prospectus supplement for an underwritten offering of common stock and pre-funded warrants, concurrent with an offering of…
- 424B5Vaxcyte filed a preliminary 424B5 prospectus supplement for an offering of convertible senior notes due October 15, 2032, with an underwriters' over-allotment…